Søren Pedersen--The START study英文版 医学资料.pptx

The START studyMilestones of Asthma Management;;; ;;To determine whether early intervention with a low dose of the inhaled corticosteroid budesonide in patients with mild, persistent asthma of <2 years’ duration would prevent the following: Time to first Severe Asthma-Related Event (SARE) (hospitalization, emergency treatment or death due to asthma) during double-blind period – first 3 years of study Change in post-bronchodilator FEV1 % predicted from baseline to the end of the 5-year study period asthma-related events (SAREs) over the first 3 years of double-blind treatment;Secondary variables;Year;A real-life study;Population;Symptoms, during the three months preceding visit 1; one of the following more than once per week, but not as often as every day: wheeze, cough, dyspnoea, chest tightness or night wakening due to any of these symptoms Reversible airway obstruction ;Reference;Patient Age Distribution;Time to First SARE; SAREs;Time to First Non-Study Glucocorticoid Treatment; Impact on Glucocorticoid Use;Prebronchodilator FEV1;Postbronchodilator FEV1;Post-bronchodilator FEV1 3-year change from baseline;;; ;(Reddel HK et al. ATS 2015);(Reddel HK et al. ATS 2015);;Severe Asthma-Related Events (SAREs);1- and 3-Year Changes in FEV1 After and Before Administration of Terbutaline (children);Percentage on inhaled steroids*;Serious AEs;Reduction in Resource Consumption Over 3 Years in Children Receiving Budesonide;Growth (cm);;;;Oral/Systemic GCS Courses;Patients on additional inhaled GCSa;Patients on ICS + LABA combinations;Additional asthma medicationDifference between Budesonide and Reference;;Summary